Cancer Brain metastases Tyrosinse Kinase Inhibitors Drug Transporters
Conditions
Interventions
- 2 11C-erlotinib PET scans. 1 with administration of a PGP/BCRP inhibitor and 1 without.
- 1 MRI of the brain.
Sponsors
Netherlands Cancer Institute - Antoni van Leeuwenhoek
Eligibility
Inclusion criteria
Inclusion criteria: The study population consists of cancer patients with advanced or metastatic solid tumors for whom no standard therapy is available or for whom a TKI which is a PgP/BCRP substrate is a standard therapeutic option (erlotinib, sunitinib, imatinib, gefitinib, sorafenib, lapatinib, crizotinib, vemurafenib).
Exclusion criteria
Exclusion criteria: - Known brain metastases; - Patients who have had previous treatment with central nervous system irradiation; - Treatment with the tyrosine kinase inhibitor used as TKI PET tracer within three half lives before the PET scans; - Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance; - Patients are not allowed to use co-medication with PgP or BCRP modulators (including OTC medication) - Patients are also not allowed to use co-medication which are PgP or BCRP substrates as this may lead to increased toxicity. - Known hypersensitivity to erlotinib, elacridar or any excipients used in the formulation of either IMPs. - Known contra-indications for a MRI scan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improved CNS penetration of 11C erlotinib after PGP/BCRP inhibitor administration. | — |
Contacts
Public ContactN. Steeghs
The Netherlands Cancer Institute Department of Medical Oncology Plesmanlaan 121
Outcome results
None listed